Trurapi (insulin aspart)
Numéro de dossier de l’APP:
22347
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
• the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin)
• continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion
• continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion
Promoteur/fabricant:
sanofi-aventis Canada Inc.
Numéro de projet de l’ACMTS:
Sans objet
Lettre-contrat de l’APP:
Conclusion du processus de négociation: